Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biodexa Pharmaceuticals PLC-AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BDRX
Nasdaq
8731
https://www.biodexapharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biodexa Pharmaceuticals PLC-AD
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
- Apr 26th, 2024 12:30 pm
Preliminary Results for the Year Ended 31 December 2023
- Apr 19th, 2024 12:00 pm
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
- Mar 28th, 2024 12:15 pm
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
- Mar 1st, 2024 1:00 pm
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
- Feb 23rd, 2024 1:30 pm
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
- Feb 8th, 2024 1:30 pm
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
- Feb 7th, 2024 1:30 pm
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
- Jan 22nd, 2024 1:30 pm
Biodexa Appoints Ann Merchant to the Board of Directors
- Dec 29th, 2023 9:05 am
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
- Dec 21st, 2023 9:00 pm
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
- Dec 19th, 2023 1:42 pm
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
- Nov 27th, 2023 2:00 pm
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
- Oct 3rd, 2023 12:30 pm
Interim results for the six months ended 30 June 2023
- Sep 29th, 2023 8:30 pm
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
- Sep 21st, 2023 12:30 pm
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
- Jul 28th, 2023 12:00 pm
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
- Jul 24th, 2023 11:30 am
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
- Jul 10th, 2023 12:00 pm
Results of Appeal of Delisting Determination
- Jul 6th, 2023 8:30 pm
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
- Jul 6th, 2023 12:15 pm
Scroll